Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rMenB+OMV NZ Booster in Adolescents and Young Adults Primed in Infancy
2024-519549-31-00Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2025
- Countries
- 4
01
Overview
Phase 3, open-label trial of meningococcal group B vaccine in meningococcal disease (2 arms), sponsored by GSK. Primary endpoint: Primary: hSBA titers against each MenB indicator strain at Visit 2 (Day 31). Started Sep 2025; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2024-519549-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519549-31-00.